CA3021681C - USE OF BETA-AGONISTS OF THYROID HORMONES - Google Patents
USE OF BETA-AGONISTS OF THYROID HORMONESInfo
- Publication number
- CA3021681C CA3021681C CA3021681A CA3021681A CA3021681C CA 3021681 C CA3021681 C CA 3021681C CA 3021681 A CA3021681 A CA 3021681A CA 3021681 A CA3021681 A CA 3021681A CA 3021681 C CA3021681 C CA 3021681C
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- compound
- receptor beta
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| US62/326,436 | 2016-04-22 | ||
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3021681A1 CA3021681A1 (en) | 2017-10-26 |
| CA3021681C true CA3021681C (en) | 2024-09-24 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3021681A Active CA3021681C (en) | 2016-04-22 | 2017-04-24 | USE OF BETA-AGONISTS OF THYROID HORMONES |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3445373B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6931042B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102407059B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017252126B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018071586A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3021681C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2992773T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX385085B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017185087A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445373B1 (en) | 2016-04-22 | 2024-08-21 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| WO2019183004A1 (en) | 2018-03-22 | 2019-09-26 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| JP2007524656A (ja) | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
| US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
| KR100890410B1 (ko) | 2004-12-08 | 2009-03-26 | 시리온 테라퓨틱스, 인크. | 레티놀-관련 질환의 치료 방법, 검정법 및 치료용 조성물 |
| MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
| EP1890768A2 (en) * | 2005-05-26 | 2008-02-27 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| US20090042857A1 (en) | 2006-02-20 | 2009-02-12 | Masuo Yamaoka | Novel Pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| BR112013032645A2 (pt) | 2011-06-21 | 2016-11-22 | Alnylam Pharmaceuticals | composições e métodos para inibição de expressão de apolipoproteína c-iii (apoc3) |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| AU2016219794A1 (en) | 2015-02-20 | 2017-09-07 | Oregon Health & Science University | Derivatives of sobetirome |
| CN108602613B (zh) | 2016-02-29 | 2020-06-16 | 菲利普莫里斯生产公司 | 铰接盖容器和坯料 |
| EP3445372A4 (en) | 2016-04-22 | 2020-03-25 | Viking Therapeutics, Inc. | USE OF THYROID BETA AGONISTS |
| EP3445373B1 (en) | 2016-04-22 | 2024-08-21 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| LT3457851T (lt) | 2016-05-18 | 2021-10-11 | Oregon Health & Science University | Sobetiromo dariniai |
-
2017
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102407059B1 (ko) | 2022-06-10 |
| AU2017252126B2 (en) | 2023-02-09 |
| US11351183B2 (en) | 2022-06-07 |
| KR20190039027A (ko) | 2019-04-10 |
| US20190321379A1 (en) | 2019-10-24 |
| US20250000880A1 (en) | 2025-01-02 |
| BR112018071586A2 (pt) | 2019-02-12 |
| US20220257618A1 (en) | 2022-08-18 |
| MX385085B (es) | 2025-03-14 |
| JP2019515033A (ja) | 2019-06-06 |
| US11951114B2 (en) | 2024-04-09 |
| EP3445373B1 (en) | 2024-08-21 |
| ES2992773T3 (en) | 2024-12-18 |
| AU2017252126A1 (en) | 2018-11-08 |
| JP6931042B2 (ja) | 2021-09-01 |
| MX2018012900A (es) | 2019-07-01 |
| US12440502B2 (en) | 2025-10-14 |
| EP3445373A4 (en) | 2019-12-18 |
| EP3445373A1 (en) | 2019-02-27 |
| CA3021681A1 (en) | 2017-10-26 |
| WO2017185087A1 (en) | 2017-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023202321B2 (en) | Use of thyroid beta-agonists | |
| US12440502B2 (en) | Use of thyroid beta-agonists | |
| KR102220175B1 (ko) | 헤테로사이클릭 글루타미나아제 억제제 | |
| AU2015274361B2 (en) | Combination therapy with glutaminase inhibitors | |
| KR20190125432A (ko) | 글루타미나제 억제제를 사용하는 병용 요법 | |
| UA123700C2 (uk) | Композиції і способи інгібування активності аргінази | |
| US11382908B2 (en) | Compositions and methods for treating inflammatory bowel disease | |
| AU2016246521A1 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| HK40064933A (en) | Use of thyroid beta-agonists | |
| HK40013781A (en) | Use of thyroid beta-agonists | |
| HK40007271A (en) | Use of thyroid beta-agonists | |
| HK40013781B (zh) | 甲状腺β-激动剂的应用 | |
| WO2017127417A1 (en) | Phosphopantothenate compounds | |
| AU2016326397A1 (en) | Conjoint therapies with inhibitors of glucose production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |
|
| EEER | Examination request |
Effective date: 20220420 |